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R-Ras can activate the phosphoinositide 3-kinase but not the
MAP kinase arm of the Ras effector pathways
Barbara M. Marte, Pablo Rodriguez-Viciana, Stefan Wennström, Patricia H.
Warne and Julian Downward
Background: The small GTPase R-Ras displays a less potent transforming
activity than the closely related Ras oncogene products. Although R-Ras has
been reported to interact with c-Raf1 and Ral-GDS in vitro, the pathways by
which it exerts its effects on cellular proliferation are not known. 
Results: Both Ras and R-Ras interact with phosphoinositide (PI) 3-kinase in
vitro, and induce elevation of the levels of PI 3-kinase lipid products in intact
cells. Unlike Ras, R-Ras does not activate Raf or mitogen-activated protein
(MAP) kinase in cells. In co-transfection assays, the serine/threonine protein
kinase PKB (or Akt) is effectively stimulated by R-Ras, Ras, mutants of Ras that
activate PI 3-kinase but not other effectors, and activated forms of PI 3-kinase.
Ras and R-Ras stimulate PKB/Akt through a non-autocrine mechanism that
involves PI 3-kinase. The constitutive activation of PI 3-kinase alone is sufficient
to activate PKB/Akt, but not the MAP kinase ERK or the stress-activated protein
kinase, Jun N-terminal kinase. Transformation assays in fibroblasts suggest that
PKB/Akt and Raf are part of distinct oncogenic signalling pathways.
Conclusion: Both the Raf–MAP kinase and PI 3-kinase–PKB/Akt pathways 
are activated by Ras, but only the PI 3-kinase-PKB/Akt pathway is activated by
R-Ras. PI 3-kinase, and downstream targets such as PKB/Akt, are likely to be
essential mediators of transformation induced by R-Ras. PI 3-kinase, as well as
Raf, is thus implicated also in Ras transformation.
Background
The R-Ras protein was originally identified because of its
high level of homology to the H-Ras, K-Ras and N-Ras
oncogene products, being about 55 % identical to each [1].
An R-Ras homologue, Ras2, has been identified in
Drosophila [2]. R-Ras and the closely related protein TC21
form a distinct branch of the Ras subfamily [3]. Despite the
considerable similarity to Ras, R-Ras has not been reported
to be activated by mutation in human tumours. In tissue-
culture experiments, activated mutants of R-Ras display
considerably reduced transforming ability compared with
activated Ras [4], and R-Ras has been reported to be unable
to transform Rat-1 fibroblasts, although it can transform
NIH 3T3 cells [4–6]. Like Ras, R-Ras interacts with the
amino-terminal regulatory region of the Raf serine/threo-
nine kinases, as does the related Ras antagonist Rap1 [7,8].
In short-term cellular assays, however, R-Ras has not been
reported to induce significant activation of Raf or the extra-
cellular signal-regulated kinase (ERK) subfamily of the
mitogen-activated protein kinases (MAP kinases), although
some, but not all, R-Ras transformed cells show partial acti-
vation of ERK [6]. R-Ras also interacts with the putative
Ras effector Ral-GDS and related exchange factors for the
Ras-related Ral proteins [9,10]; however, R-Ras is not able
to activate Ral-GDS in intact cells [11]. In terms of
upstream regulatory components, R-Ras interacts with the
GTPase-activating proteins for Ras, p120GAP and neurofi-
bromin, which stimulate R-Ras GTP hydrolysis [7,12], but
is not stimulated by Sos, the guanine nucleotide exchange
factor for Ras [13]. The extracellular stimuli that control the
activation state of R-Ras are unknown.
We have reported previously that GTP-bound Ras interacts
directly with the catalytic subunit of phosphoinositide (PI)
3-kinase, p110a, to induce its activation, particularly in
synergy with other signalling pathways [14–16]. It has also
been shown that efficient activation of PI 3-kinase by
platelet-derived growth factor (PDGF) requires Ras func-
tion [17]. PI 3-kinases are one family of target enzymes, or
effectors, of Ras, therefore, in addition to the Raf kinases
and Ral-GDS, the nucleotide exchange factors for the Ras-
related Ral proteins [18]. The role of PI 3-kinase in the
transforming activity of oncogenic Ras is currently
unknown, although PI 3-kinase activity has been reported
to be required for the growth of normal fibroblasts [19]. A
number of signalling systems have been implicated down-
stream of PI 3-kinase, including the Rho-related Ras super-
family protein Rac [20] and the serine/threonine kinases
p70S6K [21], protein kinase B (PKB or Akt) [22,23] and
novel [24] and atypical [25] isoforms of protein kinase C.
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PKB/Akt was identified by its similarity to protein kinases
A and C [26,27], and was shown to be the product of the
cellular homologue of the v-Akt retroviral oncogene [28].
The treatment of cells with growth factors such as insulin
or PDGF activates PKB/Akt through a mechanism that
requires PI 3-kinase activity and an intact pleckstrin
homology (PH) domain. The activation of PI 3-kinase has
been shown recently to be sufficient to activate PKB/Akt
in a co-transfection assay [29]. 
In this study, we have set out to investigate the pathways
used by R-Ras in regulating cell proliferation and transfor-
mation. We show that R-Ras does not activate Raf effi-
ciently, but does activate PI 3-kinase and PKB/Akt. This
pathway appears to be an important growth stimulatory
mechanism used equally well by both Ras and R-Ras.
Results
Interaction of R-Ras with effectors in vitro
To investigate possible signalling pathways used by R-Ras,
we studied the ability of R-Ras to interact with effector
molecules that have been shown to interact with Ras. Puri-
fied R-Ras was loaded with GTP or GDP, then mixed with
glutathione S-transferase (GST) fusion proteins that
included the Ras binding sites of c-Raf1, B-Raf, Ral-GDS
and PI 3-kinase p110a. R-Ras retained on glutathione
agarose in a complex with the effectors was detected by
western blotting. As shown in Figure 1, R-Ras interacted in
a GTP-dependent manner with each of these effectors. In
each case, the interaction was approximately comparable to
that with Ras (data not shown). As both Ras and R-Ras
interact with the fusion protein including amino acids
133–314 of p110a, it is likely that both interact with PI 3-
kinase at the same, or similar, sites. Indeed competition
between the two for binding to this PI 3-kinase fragment
was observed in vitro (data not shown). 
Regulation of effectors by R-Ras in intact cells
The ability of R-Ras to activate effector enzymes was
tested in whole cells. COS cells were transiently transfected
with plasmids encoding activated mutants of R-Ras  (V38,
containing a valine at position 38) or Ras (V12, the equiva-
lent to V38 in R-Ras), along with epitope-tagged c-Raf1.
Raf was immunoprecipitated from lysates of these cells, and
its activity determined by measuring its ability to activate
the MAP kinase kinase MEK. As shown in Figure 2a,
whereas activated V12 Ras efficiently stimulated Raf, V38
R-Ras was completely inactive in this assay. The ability of
R-Ras, Ras and other signalling molecules to activate ERK2
MAP kinase was also tested by co-transfection with an
epitope-tagged ERK2; the activity of the transfected ERK2
was measured following immunoprecipitation (Fig. 2b).
V38 R-Ras did not activate ERK2 in this assay, whereas
V12 Ras and activated Raf (Raf-CAAX, which is localized to
the membrane by the addition of a prenylation sequence)
activated ERK2 strongly. p110-CAAX, a strongly activated
membrane-localized form of PI 3-kinase, failed to activate
ERK2. In addition, some mutants of the effector site of Ras
were assayed. ERK2 was not activated by V12 A38 Ras (a
total loss-of-function mutant which is unable to bind to any
effectors) or by V12 C40 Ras (a mutant which is unable to
bind to Raf or Ral-GDS, but which interacts with PI 3-
kinase, albeit not as strongly as wild-type; P.R-V., P.H.
Warne and J.D., unpublished observations). ERK2 was acti-
vated by V12 E38 Ras, a mutant which is able to bind to
Raf, although not as efficiently as wild-type, but which does
not bind to PI 3-kinase or Ral-GDS (P.R-V., P.H. Warne
and J.D., unpublished observations). We conclude that the
ERK2 MAP kinase can be activated by an interaction
between Ras and Raf, but not by an interaction between R-
Ras and Raf, and that ERK2 activation is not caused by the
activation of PI 3-kinase.
As well as Raf and ERK2, we studied the ability of R-Ras to
activate the stress-activated kinase Jun N-terminal kinase
(JNK) (Fig. 2c). As reported previously [30,31], V12 Rac, v-
Src and anisomycin stimulated JNK strongly, whereas V12
Ras activated JNK only weakly. Similar results were
observed for both the p54 and p46 forms of JNK. An acti-
vated form of Dbl, a guanine nucleotide exchange factor for
Rho family proteins, was also able to stimulate JNK, pre-
sumably acting through endogenous Cdc42 or Rac. R-Ras
was completely unable to stimulate JNK in this assay, as
was activated PI 3-kinase. This result was somewhat unex-
pected, as study of the actin cytoskeleton in fibroblasts has
indicated that PI 3-kinase appears to be able to activate
Rac, an activator of JNK, in that system (see Discussion).
The ability of R-Ras to regulate PI 3-kinase was investi-
gated by measuring the levels of the lipids phosphatidyli-
nositol (3,4) P2 (PI(3,4)P2) and phosphatidylinositol (3,4,5)
P3 (PIP3) in transiently transfected COS cells. Upon tran-
sient transfection into COS cells, activated Ras synergizes
strongly with wild-type p110a to give increased levels of
Figure 1
R-Ras binds to c-Raf1, B-Raf, Ral-GDS and PI 3-kinase (p110a) in a
GTP-dependent manner in vitro. The Ras-binding domains of c-Raf1
[53], B-Raf, Ral-GDS and p110a [15] were expressed as GST-fusion
proteins and immobilized on glutathione beads. Purified R-Ras protein
was loaded with either GDP or GTP and incubated with the beads.
After washing, the bound R-Ras protein was electrophoresed on a
15 % SDS gel and detected with an anti-R-Ras antibody by western
blotting. The R-Ras band is indicated by an arrow.
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the PI 3-kinase product lipids PI(3,4)P2 and PIP3 [14,15].
As shown in Figure 2d, R-Ras was also able to elevate the
levels of PI(3,4)P2 and PIP3 in this way. In this assay,
p110a alone showed constitutive activation when it was
localized to the plasma membrane by a carboxy-terminal
farnesylation signal from H-Ras (CAAX; [32]). In the
absence of overexpressed wild-type p110a, both activated
Ras and R-Ras give only modestly elevated levels of
PI(3,4)P2 and PIP3 ([14] and data not shown); this is
presumably due to the relatively small fraction of cells
expressing the transfected genes. Thus, R-Ras is able to
activate the PI 3-kinase pathway in cells, with an effic-
iency similar to that of Ras.
The effect of activating PI 3-kinase on the activity of
PKB/Akt was investigated by immunoprecipitating
PKB/Akt tagged with a hemagglutinin (HA) epitope [23]
from transiently transfected COS cells, and assaying for its
ability to phosphorylate histone 2B [22]. p110-CAAX, but
not a kinase-inactive p110 mutant, caused a robust activa-
tion of PKB/Akt (Fig. 3a). We also used the same assay on
NIH 3T3 cells overexpressing the insulin receptor (A14
cells; Fig. 3b): PKB/Akt was stimulated 22-fold by p110-
CAAX, 16-fold by insulin treatment, 13-fold by activated
V38 R-Ras alone, 19-fold by activated V12 Ras alone, and
8-fold by v-Src (which has also been shown to elevate PIP3
levels [14]). However, activated Raf and the Rho-related
GTPase Rac were unable to influence PKB/Akt activity. A
point mutation in the PH domain of PKB/Akt, R25C (with
an arginine residue replacing the cysteine at position 25
[22]), completely blocked its activation by all these
stimuli. It would appear, therefore, that all the stimuli
capable of activating PI 3-kinase, including R-Ras, are
able to activate PKB/Akt. Immunoblotting of PKB/Akt
from A14 cells showed that there was a marked shift in
apparent molecular weight in cells expressing PI 3-kinase,
Ras or R-Ras, probably indicating an alteration in the
phosphorylation state of PKB/Akt (Fig. 3c). 
R-Ras activation of PKB/Akt is through a non-autocrine
mechanism involving PI 3-kinase
A problem in interpreting data from transient transfection
experiments is that the assay is performed over a suff-
iciently long period for autocrine production of growth
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Figure 2
R-Ras activates PI 3-kinase in vivo, but not
Raf, MAP kinase or JNK. (a) Raf activity was
measured in COS-7 cells by co-transfecting
V12 Ras or V38 R-Ras with Myc-tagged
c-Raf1. After 48 h, Raf was
immunoprecipitated and assayed in a coupled
assay for its ability to activate MEK. (b) COS-7
cells were transfected with 1 mg Myc-tagged
MAP kinase (p42 ERK2) and 1 mg of the
indicated plasmids. After 48 h, ERK2 was
immunoprecipitated with the 9E10 antibody.
Activity was determined using MBP (myelin
basic protein) as a substrate. Reactions were
electrophoresed on a 15 % SDS gel and
phosphorylated MBP was quantified with a
phosphoimager. (c) COS-7 cells were
transfected with 1 mg hemagglutinin (HA)-
tagged JNK (p54 SAPK) and 1 mg of the
indicated plasmids. After 48 h, JNK was
immunoprecipitated with the 12CA5 antibody.
Activity was determined using GST–Jun as a
substrate. Reactions were run on a 15 % SDS
gel and quantified with a phosphoimager. (d)
48 h after transfection with the indicated
plasmids, COS-7 cells were labelled with 0.25
mCi 32P-orthophosphate for 5 h. Lipids were
extracted and analysed by HPLC as described
in [14]. 
Control V12
Ras
V38 
R-Ras
Fo
ld
 a
ct
iv
at
io
n 
(M
B
P
 p
ho
sp
ho
ry
la
tio
n)
Fo
ld
 a
ct
iv
at
io
n 
(M
B
P
 p
ho
sp
ho
ry
la
tio
n)
Fo
ld
 a
ct
iv
at
io
n 
(G
S
T–
Ju
n 
ph
os
ph
or
yl
at
io
n)
cp
m
 ( 
x 1
03
)
Co
ntr
ol
    
V1
2 R
as

    
 V1
2 A
38
 R
as
 
    
V1
2 E
38
 R
as

    
V1
2 C
40
 R
as

Ra
f-C
AA
X
p1
10
-C
AA
X
V3
8 R
-R
as

Co
ntr
ol
    
V1
2 R
as

V1
2 R
ac

p1
10
-C
AA
X
An
iso
my
cin

v-S
rc
V3
8 R
-R
as

∆ D
bl
Ve
cto
r
p1
10
 wt

p1
10
-CA
AX

    
 V1
2 R
as
V3
8 R
-Ra
s
+ p
11
0 w
t
+ p
11
0 w
t
PI(3,4)P
PI(3,4,5)P
25
20
15
10
5
0
15
10
5
0
30
25
20
15
10
5
0
250
200
150
100
50
0
(a) (b)
(c) (d)
2
3
66 Current Biology, Vol 7 No 1
factors to occur, which might contribute to the activation
of downstream enzymes [33]. The activation of PKB/Akt
by R-Ras and Ras may therefore be mediated by the
production of autocrine growth factors which activate PI -
3-kinase. To investigate this question, R-Ras or Ras were
either co-transfected with epitope-tagged PKB/Akt into
COS cells, or R-Ras or Ras and PKB/Akt were transfected
into separate populations of cells which were subse-
quently mixed and cultured together. R-Ras and Ras acti-
vated PKB/Akt only when they were present in the same
cells, and not when they were expressed in neighbouring
cells in the same culture (Fig. 4). It is unlikely, therefore,
that R-Ras or Ras activates PKB/Akt by an autocrine
mechanism. 
As shown in Figure 3, there was a strong correlation
between activation of PI 3-kinase and activation of
PKB/Akt. To investigate this observation further, partial
loss-of-function effector mutants in Ras were studied.
PKB/Akt was activated by V12 C40 Ras, although more
weakly than by V12 Ras or V38 R-Ras, whereas V12 E38
Ras and V12 A38 Ras (which is entirely inactive) both
failed to activate PKB/Akt (Fig. 5a). 
The connection between PI 3-kinase activation and
PKB/Akt activation was tested directly using PI 3-kinase
inhibitors. To investigate whether PI 3-kinase activity was
required for R-Ras and Ras to stimulate PKB/Akt, the
well-characterized PI 3-kinase inhibitor LY294002 was
used [34]. LY294002 inhibited the activation of PKB/Akt
by V38 R-Ras and V12 Ras in A14 cells, with approxi-
mately 1 mM being required for 50 % inhibition (Fig. 5b);
this value is similar to the half-maximal inhibitory concen-
tration (IC50) for PI 3-kinase [34]. A similar sensitivity to
LY294002 was observed for the activation of PKB/Akt by
V12 C40 Ras, p110-CAAX, v-Src and insulin (Fig. 5b,c). A
second PI 3-kinase inhibitor, wortmannin, also inhibited
this PKB/Akt activation at 100 nM (data not shown).
Figure 3
Activation of PKB/Akt by R-Ras, H-Ras or
membrane-targeted PI 3-kinase. (a) PKB/Akt
activity was measured in COS-7 cells co-
transfected with vector alone, p110-CAAX or
the kinase-inactive version p110-CAAX R916P
(with an arginine residue replacing the proline at
position 916; [52]) (upper panel). Western-blot
analysis of the immunoprecipitations showed
equal expression levels of PKB/Akt (middle
panel). The expression of active and inactive
p110-CAAX was compared in total lysates
(lower panel). (b) A14 cells were transfected
with HA-PKB/Akt (wild-type or the R25C
mutant) plus the indicated plasmids. Some cells
were treated with 10 mg ml–1 insulin for 2 min.
PKB/Akt activity was determined as described
in Materials and methods. (c) HA-PKB/Akt was
immunoprecipitated from A14 cells co-
transfected with the indicated plasmids and
separated on a 15 % SDS-PAGE gel, which
was then probed with an anti-PKB/Akt antibody.
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Figure 4
The activation of PKB/Akt by R-Ras and H-Ras is not autocrine. COS-
7 cells were co-transfected with HA-PKB/Akt and V38 R-Ras or V12
Ras (Plus), or R-Ras, Ras and HA-PKB/Akt were transfected into
separate pools of cells which were subsequently mixed (Mix). Kinase
activity was determined as described in Materials and methods.
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Neither inhibitor is completely specific for PI 3-kinase,
but, at the concentrations used, LY294002 and wortman-
nin are the best available means for inhibiting PI 3-kinase.
The role of the PKB/Akt pathway in transformation
The data presented here indicate that PKB/Akt acts as a
target of PI 3-kinase activity and as part of the effector
signalling pathways of both Ras and R-Ras. By contrast, Ras
also uses the Raf–MAP kinase pathway, but R-Ras does
not. To investigate the potential contribution of PKB/Akt
to the transformation of cultured fibroblasts by R-Ras and
Ras, NIH 3T3 cells were transfected with a construct
encoding a PKB/Akt which had been activated by fusion to
a retroviral gag sequence [23]. This activated PKB/Akt
alone was unable to transform these cells, as were the
V12 C40 Ras and V12 E38 Ras mutants (which activate PI
3-kinase and Raf, respectively), but PKB/Akt synergized
with V12 E38 Ras to give transformation (Table 1).
PKB/Akt did not synergize with V12 G37 Ras (which acti-
vates Ral-GDS) or with V12 C40 Ras, presumably because
it acts on the same pathway. Thus PKB/Akt, although a
very weak oncogene by itself, can provide a transforming
signal which complements that of the Raf pathway. 
Discussion
Here we have shown that the Ras subfamily member R-Ras
activates PI 3-kinase and PKB/Akt in cells with an effi-
ciency similar to that of Ras, but is extremely inefficient at
activating Raf, despite interacting strongly with Raf in vitro.
The reason for the poor ability of R-Ras to activate Raf is
not clear, but may be due to differences in the intracellular
localization of Ras and R-Ras. Ras is found exclusively at
the plasma membrane, but the localization of R-Ras has not
been reported, and may be on intracellular membranes.
The ability of Ras to bring c-Raf1 to the plasma membrane,
where it may be acted on by other components of the acti-
vation machinery, is thought to be a crucial part of its func-
tion [35,36]. It has been reported that some clones of NIH
3T3 cells transformed by R-Ras exhibit partial activation of
ERK2 MAP kinase [6]; as R-Ras does not activate Raf or
ERK2 in transient assays in NIH 3T3 or COS cells, it is
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R-Ras and Ras activate PKB/Akt via PI 3-kinase. PKB/Akt activity was
measured in COS-7 (a,b) or A14 (c) cells after co-transfection with
the indicated plasmids. In (b,c), cells were incubated with increasing
concentrations of LY294002 or the carrier DMSO for 2 h prior to lysis.
Insulin treatment (10 mg ml–1) was carried out for 2 min.
Table 1
Transformation of NIH/3T3 cells by Ras mutants and 
gag-PKB/Akt. 
Plasmids Plasmid concentration Relative number of foci
V12 Ras 50 ng 0.3
500 ng 1
V38 R-Ras 50 ng 0.06
500 ng 0.4
2 mg 1
v-Akt 0.03
v-Akt + G37 Ras 0
v-Akt + E38 Ras 0.29
v-Akt + C40 Ras 0
G37 Ras 0
E38 Ras 0.03
C40 Ras 0
E38 Ras + G37 Ras 0
E38 Ras + C40 Ras 0
Plasmids encoding V12 Ras, V38 R-Ras, other Ras mutants (in a V12
background) and gag-PKB/Akt (v-Akt) were transfected into NIH/3T3
cells either alone or in combinations. Focus-formation assays were
performed over two weeks. Numbers represent data from at least two
independent experiments.
possible that this activation of ERK2 is the result of other
causes and has been selected for during the transformation
assay. 
The exact mechanism involved in the activation of PI 3-
kinase by Ras and R-Ras has not been elucidated, although
it is clear that purified, post-translationally modified
Ras–GTP can activate purified PI 3-kinase in a liposome
system in vitro [15]. There may not be a requirement for
this interaction to occur at the plasma membrane rather
than any other membrane. As R-Ras activates both PI 3-
kinase and its downstream target PKB/Akt,  the second-
messenger 3′ phosphorylated phosphoinositides generated
may be as available to PKB/Akt as are the lipids generated
in response to Ras or p110-CAAX expression. The data
shown in Figure 4 indicate that the mechanism involved is
likely to be the direct stimulation of PI 3-kinase by interac-
tion with Ras and R-Ras proteins, rather than through a
pathway mediated by autocrine growth factors.
The activation of PKB/Akt by Ras and membrane-localized
p110 has been reported recently [29]. In co-transfection
experiments described in that report and here, activation of
PI 3-kinase appears sufficient to stimulate PKB/Akt.
However, in the function of normal cellular growth-factor
signalling pathways, it is likely that a second signal in addi-
tion to PI 3-kinase is required: for example, there is consid-
erable discrepancy between the ability of growth factors to
activate PI 3-kinase and PKB/Akt, although PI 3-kinase is
clearly required [22,23,37]. PIP3, and to a lesser extent
PI(3,4)P2, have been reported to bind specifically to the PH
domain of PKB/Akt [38]; the exact mechanism whereby
this interaction can be sufficient to cause PKB/Akt activa-
tion in whole cells is unclear, but may involve presentation
of the enzyme to other kinases, possibly at the plasma
membrane, alteration of the dimerization state of PKB/Akt,
or direct allosteric regulation of its kinase activity
[22,37,39,40]. The only downstream target of PKB/Akt
identified to date is glycogen synthase kinase-3 [41], but
others doubtless exist. The frequent overexpression of the
closely related Akt2/PKBb in ovarian and pancreatic cancer
[42,43] lends weight to the idea that pathways controlled by
PKB/Akt are important in human tumourigenesis. Our
demonstration that R-Ras is as able as Ras to activate
PKB/Akt shows that this pathway may be an important
component of the signalling machinery used by R-Ras, as
well as Ras, in cellular transformation. 
As R-Ras can activate PI 3-kinase and PKB/Akt, is it
involved in PKB/Akt activation induced by growth factors?
The dominant-negative N17 Ras mutant is able to inhibit
(by 60–70 %) the activation of PKB/Akt by PDGF, insulin
and epidermal growth factor (EGF), suggesting that Ras is
of major importance in this pathway ([22] and our
unpublished observations). No effect of expressing
dominant-negative R-Ras on activation of PKB/Akt by
these growth factors has yet been seen. However, the
growth stimuli that normally activate R-Ras are currently
unknown. It is perhaps likely that R-Ras responds to differ-
ent upstream signals to Ras, but at present these remain
elusive. It is unlikely that the ability of R-Ras to activate PI
3-kinase and PKB/Akt is simply the result of targeting PI 3-
kinase to its substrates in any membrane, as another Ras
subfamily protein, Rap1a, is unable to activate either PI 3-
kinase or Akt in intact cells ([15] and our unpublished
observations).
Unlike Klippel et al. [29], we were not able to see any ability
of activated PI 3-kinase to stimulate the stress-activated
kinase JNK in co-transfection assays. The reason for this
discrepancy is not clear. Ras shows modest activation of
JNK, as reported previously by others [30,31], but R-Ras
does not. Ras-induced activation of JNK could be mediated
by direct interaction of Ras with MEKK (MAP kinase
kinase kinase; [44]) or with JNK itself [45]; it is not known
whether R-Ras interacts with these targets. The ability of
Ras and R-Ras to activate PI 3-kinase similarly, but of only
Ras to activate JNK, indicates that it is unlikely that the
activation of JNK by Ras is mediated by PI 3-kinase. More-
over, PI 3-kinase inhibitors such as wortmannin and
LY294002 are not able to block the activation of JNK
induced by Ras, Src or growth factors; on the contrary, treat-
ment of cells with these inhibitors alone leads to activation
of JNK (our unpublished results and [46]). It is possible that
PI 3-kinase may contribute in some way to JNK activation,
but that other signalling inputs are required. For example, it
has been reported recently that the adaptor protein Nck
may be involved in linking receptor tyrosine kinases to the
activation of PAK (p21-activated kinase) and JNK [47].
The biological function of R-Ras has been obscure.
Microinjection experiments failed to find an effect of R-Ras
protein on DNA synthesis or cell morphology, although it is
possible that R-Ras function was compromized by defective
post-translational modification of the bacterially expressed
protein [7]. Activated mutant forms of R-Ras have been
found to induce transformation of NIH 3T3 fibroblasts, but
not Rat-1 fibroblasts [4–6]. R-Ras transformation differs
from Ras transformation in that R-Ras-transformed NIH
3T3 cells do not display the refractile morphology of Ras-
transformed cells [6]. This is perhaps surprising, given that
the PI 3-kinase pathway is thought to have a major short-
term impact on the actin cytoskeleton; however, the events
required for long-term morphological transformation are
unknown, and certainly require more than just PI 3-kinase
activation (P.R-V. and J.D., unpublished results). When co-
expressed with Myc, R-Ras will give morphological trans-
formation [6]. Presumably, Ras is able to provide all the
signals necessary to cause morphological transformation,
whereas R-Ras provides only some. R-Ras synergizes
strongly with Raf in the transformation of NIH 3T3 cells,
indicating that R-Ras lacks the ability to activate the Raf
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pathway [5]. From the transformation assays reported
here, it appear that the Raf–MAP kinase and the PI 3-
kinase–PKB/Akt pathways act synergistically in the trans-
formation of murine fibroblasts. It is clear that activation
of the PI 3-kinase–PKB/Akt pathway alone is not suffi-
cient to give efficient transformation of NIH 3T3 cells,
even though it synergizes strongly with the Raf pathway.
Other aspects of R-Ras function have been reported. R-Ras
may interact with Bcl-2, an important regulator of pro-
grammed cell death, and has been suggested to promote
apoptosis in IL-3 dependent cells [48,49]. However, the
significance of this observation remains controversial. In
addition, R-Ras has recently been reported to promote inte-
grin activation [50]; the mechanism involved has not been
established, but could involve PI 3-kinase [51]. The signifi-
cance of this to R-Ras-induced transformation is unclear.
The data presented in this paper establish, for the first
time, an effector pathway used by R-Ras in cells — the PI
3-kinase–PKB/Akt pathway. Future work will address other
signalling mechanisms that might be used by R-Ras in vivo,
and the regulatory mechanisms that act upstream of R-Ras.
Conclusions
The potent transforming potential of Ras proteins has
been well characterized. By contrast, the closely related
GTPase R-Ras is less well understood, despite being
expressed ubiquitously in a wide range of species. Ras
interacts with a number of target enzymes in vitro and has
been shown to activate Raf and PI 3-kinase in vivo. R-Ras
is able to interact with the same effectors, but can only
activate PI 3-kinase, and not Raf, in whole cells. Both Ras
and R-Ras can activate PKB/Akt, a serine/threonine
kinase downstream of PI 3-kinase that itself has trans-
forming potential, through a non-autocrine mechanism.
Constitutive activation of PI 3-kinase alone is sufficient to
activate PKB/Akt, but not the MAP kinase ERK or the
stress-activated protein kinase JNK. Transformation
assays in fibroblasts show that PKB/Akt and Raf are part of
distinct oncogenic signalling pathways which act synergis-
tically. PI 3-kinase and downstream targets such as
PKB/Akt are likely to be essential mediators of R-Ras-
induced transformation. This work also emphasizes the
likely importance of PI 3-kinase in Ras transformation. 
Materials and methods
Plasmids, proteins and antibodies
The Ras effector mutants were made in a V12 background in pSG5
(P.R-V., P.H. Warne and J.D., unpublished observations). p110a-CAAX
and p110a-CAAX R916 [52] in pSG5 will be described elsewhere
(S.W. and J.D, unpublished observations). HA-PKB/Akt (wild-type and
R25C) and gag-PKB/Akt were a generous gift from B. Burgering and
P.Coffer [23]. DDbl was kindly provided by M. Olson and A. Hall.
GST-fusion proteins encompassing the Ras binding sites of c-Raf , Ral-
GDS and p110a are described in [14,15,53] and P.R-V., P.H.Warne
and J.D. unpublished observations). Amino acids 130–310 of quail B-Raf
[54] were cloned into the pGEX (Pharmacia) vector for expression as a
GST fusion protein. The Glu-tagged R-Ras baculovirus vector was
obtained from F. McCormick (Onyx). R-Ras was purified from Sf9 cells
with an antibody column. The polyclonal antiserum recognizing p110
(kindly provided by L. Claeson-Welsh and R. Hooshman-Rad) was raised
against the carboxy-terminal 14 amino acids of bovine p110a.
R-Ras binding assays in vitro
50 ml of binding buffer (50 mM Hepes pH7.5, 50 mM NaCl, 5 mM MgCl2,
5 mg ml–1 BSA) containing 0.5 mM R-Ras and 200 mM GDP or GTP was
incubated at 37 °C for 5 min. Magnesium chloride was added to 10 mM
followed by 20 ml of 1:1 suspension of glutathione agarose beads bound
to GST-fusion protein. The volume was made up to 200ml with phos-
phate buffered saline (PBS), 5 mM MgCl2, 1 % Triton X-100 ,and the
mixture was rotated at 4 °C for 2 h. The beads were then washed consec-
utively in 1 ml PBS containing 1 % Triton X-100, 5 mM MgCl2, then in 1
ml 100 mM Tris pH 7.5, 500 mM LiCl, 5 mM MgCl2, and then in 1 ml of
50 mM Tris pH7.5, 100 mM NaCl, 5 mM MgCl2. The beads were finally
resuspended in SDS PAGE sample buffer. Bound R-Ras was detected
by immunoblotting using an anti-R-Ras antibody (Santa-Cruz).
Kinase assays
HA-PKB/Akt activity was assayed 48 h after transfection of COS-7 or
A14 cells with the lipofectamine kit from Gibco/BRL. HA-PKB/Akt in the
cells was immunoprecipitated with the 12CA5 antibody. The immunopre-
cipitates were washed and assays were performed as in [23], except that
histone 2B was used as a substrate. HA-PKB/Akt was detected on
western blots with an polyclonal antibody directed against the carboxyl
terminus of PKB/Akt [22]. Raf activity was assayed by co-transfection of
a myc-tagged c-Raf1 construct and performing a coupled MEK/ERK2
kinase assay on 9E10 immunoprecipitates as described [55]. Myc-
tagged p42 was immunoprecipitated from transfected cells with 9E10
antibody and MBP phosphorylation was determined as described  [55].
HA-JNK (p54 SAPK) was immunoprecipitated with 12CA5 antibody.
Activity was determined as for MAPK, using GST-Jun as a substrate.
Transformation assays in NIH/3T3 cells
Low passage NIH/3T3 cells were seeded at 105 per well in 6-well dishes
the day before lipofection with 0.5–2.5mg of each plasmid, apart from
V12 Ras and V38 R-Ras where the indicated concentrations were used
(Table 1). Two days later, the cells were transferred to 10 cm plates.
After reaching confluency, they were kept in DME medium containing 5
% calf serum for 2 weeks, after which they were stained with O.5 %
crystal violet to visualize foci. On average, about 150 foci were obtained
with 10 ng of V12 Ras.
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Erratum
R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm 
of the Ras effector pathways
Barbara M. Marte, Pablo Rodriguez-Viciana, Stefan Wennström, Patricia H. Warne and 
Julian Downward
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R-Ras and Ras activate PKB/Akt via PI 3-kinase. PKB/Akt activity was
measured in COS-7 (a,b) or A14 (c) cells after co-transfection with
the indicated plasmids. In (b,c), cells were incubated with increasing
concentrations of LY294002 or the carrier DMSO for 2 h prior to lysis.
Insulin treatment (10 mg ml–1) was carried out for 2 min.
Current Biology 1997, 7:63–71.
In this paper, which appeared in the 1 January 1997 issue of Current Biology, the labelling on the x axis of Figure 5a was
inadvertently omitted. The correct version of the figure can be seen below.
